Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)

Psoriatic arthritis (PsA) is a chronic immunoinflammatory disease of the joints, spine and entheses from the group of spondyloarthritis, which is usually observed in patients with psoriasis. In recent years, the axial form of PsA (axPsA) has been actively researched. However, there is insufficient d...

Full description

Saved in:
Bibliographic Details
Main Authors: T. V. Korotaeva, E. E. Gubar, E. Yu. Loginova, Y. L. Korsakova, E. A. Vasilenko, I.-D. Yu. Ilyevsky, L. V. Ivanova, E. Yu. Akulinushkina, P. A. Shesternya, O. V. Matveychuk, Yu. Yu. Grabovetskaya, A. A. Barakat, M. A. Korolev, E. V. Zonova, O. A. Georginova, I. V. Kolotilina, I. M. Marusenko, I. B. Vinogradova, O. B. Nesmeyanova, N. E. Grigoriadi, A. V. Petrov, D. G. Krechikova, T. V. Kropotina, S. P. Yakupova, V. I. Mazurov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2023-12-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/1498
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849242123715477504
author T. V. Korotaeva
E. E. Gubar
E. Yu. Loginova
Y. L. Korsakova
E. A. Vasilenko
I.-D. Yu. Ilyevsky
L. V. Ivanova
E. Yu. Akulinushkina
P. A. Shesternya
O. V. Matveychuk
Yu. Yu. Grabovetskaya
A. A. Barakat
M. A. Korolev
E. V. Zonova
O. A. Georginova
I. V. Kolotilina
I. M. Marusenko
I. B. Vinogradova
O. B. Nesmeyanova
N. E. Grigoriadi
A. V. Petrov
D. G. Krechikova
T. V. Kropotina
S. P. Yakupova
V. I. Mazurov
author_facet T. V. Korotaeva
E. E. Gubar
E. Yu. Loginova
Y. L. Korsakova
E. A. Vasilenko
I.-D. Yu. Ilyevsky
L. V. Ivanova
E. Yu. Akulinushkina
P. A. Shesternya
O. V. Matveychuk
Yu. Yu. Grabovetskaya
A. A. Barakat
M. A. Korolev
E. V. Zonova
O. A. Georginova
I. V. Kolotilina
I. M. Marusenko
I. B. Vinogradova
O. B. Nesmeyanova
N. E. Grigoriadi
A. V. Petrov
D. G. Krechikova
T. V. Kropotina
S. P. Yakupova
V. I. Mazurov
author_sort T. V. Korotaeva
collection DOAJ
description Psoriatic arthritis (PsA) is a chronic immunoinflammatory disease of the joints, spine and entheses from the group of spondyloarthritis, which is usually observed in patients with psoriasis. In recent years, the axial form of PsA (axPsA) has been actively researched. However, there is insufficient data on approaches to the diagnosis and treatment of patients with axPsA in real-life clinical practice. This article presents the results of an interim analysis of data from a non-interventional multicenter observational study on the treatment of patients with axPsA in real-life clinical practice (NiSaXPA) in Russian centers.Objective: to identify patients with axPsA, their characteristics and describe treatment tactics in real-life clinical practice.Material and methods. Patients with PsA who met the inclusion criteria were prospectively followed up during routine visits to a rheumatologist. Participants' axial radiographs were uploaded to a database in order for it to be confirmed the presence or absence of axPsA by two independent experts, a rheumatologist and a radiologist. Patients with a confirmed axPsA diagnosis participated in a further data collection phase (Visit 2, week 24).Results and discussion. Six hundred patients were enrolled into the study. At the time of analysis, 386 (64.3%) of them (209 men and 177 women) were screened for axPsA. The diagnosis of axPsA was confirmed in 241 (62.4%) cases; these patients formed the Per Protocol (PP) population. The mean age of patients with axPsA in the PP population was 46.30±12.6 years and the body mass index (BMI) was 27.4±5.2 kg/m2 . In 14.9% of patients, the duration of psoriasis was less than 1–5 years, in 21.5% – 5–10 years and in 63.6% – more than 10 years. The duration of PsA symptoms was less than 1–5 years in 31.2 % of patients, 5–10 years in 31.6 % and more than 10 years in 37.2 %. Low disease activity (BASDAI ˂ 4) was achieved in 33.3 % of patients with axPsA at visit 1 and in 64.3 % at visit 2; the BASDAI index declined on average from 4.67±1.95 to 3.31±1.89 points.In real-life clinical practice, patients were most frequently prescribed non-steroidal anti-inflammatory drugs (NSAIDs) – 88.7% and 71.7% (visits 1 and 2, respectively), and synthetic disease-modifying antirheumatic drugs (sDMARDs) –79.1% and 70.7%, respectively; therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) was initiated in 40.2% and 60.6% of patients, respectively.Conclusion. The results of the interim analysis of this observational study showed that in 87.2% of patients who met the CASPAR criteria for PsA there was a suspicion of axial manifestations of PsA on the primary care level. However, only 62.4% of them had a confirmed diagnosis of axPsA on centralized expert assessment, which may indicate a possible overdiagnosis of axial lesions in real-life practice and emphasizes the importance of collaboration between a rheumatologist and a radiologist when analyzing the results of imaging studies. 33.3% of patients with axPsA had low disease activity according to BASDAI at baseline and 64.3% after 24 weeks, meaning that the disease was only adequately controlled in one third of cases despite therapy; the number of these patients doubled after a change in therapy. In real-world clinical practice, patients with axPsA are most commonly prescribed drugs from the NSAID and sDMARD groups; the frequency of use of biologic drugs varied between 40.2 and 60.6% by the end of the observation period.
format Article
id doaj-art-2ce507c9aff047a4aa939b461df954ab
institution Kabale University
issn 1996-7012
2310-158X
language Russian
publishDate 2023-12-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-2ce507c9aff047a4aa939b461df954ab2025-08-20T03:59:54ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2023-12-01176223010.14412/1996-7012-2023-6-22-302632Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)T. V. Korotaeva0E. E. Gubar1E. Yu. Loginova2Y. L. Korsakova3E. A. Vasilenko4I.-D. Yu. Ilyevsky5L. V. Ivanova6E. Yu. Akulinushkina7P. A. Shesternya8O. V. Matveychuk9Yu. Yu. Grabovetskaya10A. A. Barakat11M. A. Korolev12E. V. Zonova13O. A. Georginova14I. V. Kolotilina15I. M. Marusenko16I. B. Vinogradova17O. B. Nesmeyanova18N. E. Grigoriadi19A. V. Petrov20D. G. Krechikova21T. V. Kropotina22S. P. Yakupova23V. I. Mazurov24V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyClinic of High Technologies N.I. Pirogov Saint-Petersburg State UniversityCity Polyclinic №64, Moscow Health DepartmentRepublican Clinical Diagnostic Center of the Ministry of Health of the Udmurt RepublicRepublican Clinical Diagnostic Center of the Ministry of Health of the Udmurt RepublicProfessor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of RussiaPodolsk City Clinical Hospital № 3Regional Clinical Hospital of Kaliningrad RegionV.P. Demihov City Clinical Hospital, Moscow Health DepartmentResearch Institute of Clinical and Experimental Lymphology – branch of the Institute of Cytology and Genetics of Russian Academy of ScienceMedical Center “Zdorovaya Semya”Lomonosov Moscow State UniversityCity Clinical Hospital №3V.A. Baranov Republican HospitalUlyanovsk Regional Clinical HospitalChelyabinsk Regional Clinical HospitalPerm Regional Clinical HospitalN.A. Semashko Republican Clinical HospitalRegional Rheumatological CenterRegional Clinical HospitalMedical Center “Vashe Zdorov’e”North-Western State Medical University named after I.I. MechnikovPsoriatic arthritis (PsA) is a chronic immunoinflammatory disease of the joints, spine and entheses from the group of spondyloarthritis, which is usually observed in patients with psoriasis. In recent years, the axial form of PsA (axPsA) has been actively researched. However, there is insufficient data on approaches to the diagnosis and treatment of patients with axPsA in real-life clinical practice. This article presents the results of an interim analysis of data from a non-interventional multicenter observational study on the treatment of patients with axPsA in real-life clinical practice (NiSaXPA) in Russian centers.Objective: to identify patients with axPsA, their characteristics and describe treatment tactics in real-life clinical practice.Material and methods. Patients with PsA who met the inclusion criteria were prospectively followed up during routine visits to a rheumatologist. Participants' axial radiographs were uploaded to a database in order for it to be confirmed the presence or absence of axPsA by two independent experts, a rheumatologist and a radiologist. Patients with a confirmed axPsA diagnosis participated in a further data collection phase (Visit 2, week 24).Results and discussion. Six hundred patients were enrolled into the study. At the time of analysis, 386 (64.3%) of them (209 men and 177 women) were screened for axPsA. The diagnosis of axPsA was confirmed in 241 (62.4%) cases; these patients formed the Per Protocol (PP) population. The mean age of patients with axPsA in the PP population was 46.30±12.6 years and the body mass index (BMI) was 27.4±5.2 kg/m2 . In 14.9% of patients, the duration of psoriasis was less than 1–5 years, in 21.5% – 5–10 years and in 63.6% – more than 10 years. The duration of PsA symptoms was less than 1–5 years in 31.2 % of patients, 5–10 years in 31.6 % and more than 10 years in 37.2 %. Low disease activity (BASDAI ˂ 4) was achieved in 33.3 % of patients with axPsA at visit 1 and in 64.3 % at visit 2; the BASDAI index declined on average from 4.67±1.95 to 3.31±1.89 points.In real-life clinical practice, patients were most frequently prescribed non-steroidal anti-inflammatory drugs (NSAIDs) – 88.7% and 71.7% (visits 1 and 2, respectively), and synthetic disease-modifying antirheumatic drugs (sDMARDs) –79.1% and 70.7%, respectively; therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) was initiated in 40.2% and 60.6% of patients, respectively.Conclusion. The results of the interim analysis of this observational study showed that in 87.2% of patients who met the CASPAR criteria for PsA there was a suspicion of axial manifestations of PsA on the primary care level. However, only 62.4% of them had a confirmed diagnosis of axPsA on centralized expert assessment, which may indicate a possible overdiagnosis of axial lesions in real-life practice and emphasizes the importance of collaboration between a rheumatologist and a radiologist when analyzing the results of imaging studies. 33.3% of patients with axPsA had low disease activity according to BASDAI at baseline and 64.3% after 24 weeks, meaning that the disease was only adequately controlled in one third of cases despite therapy; the number of these patients doubled after a change in therapy. In real-world clinical practice, patients with axPsA are most commonly prescribed drugs from the NSAID and sDMARD groups; the frequency of use of biologic drugs varied between 40.2 and 60.6% by the end of the observation period.https://mrj.ima-press.net/mrj/article/view/1498axial psoriatic arthritisnon-interventional studydiagnosticstreatment tactics
spellingShingle T. V. Korotaeva
E. E. Gubar
E. Yu. Loginova
Y. L. Korsakova
E. A. Vasilenko
I.-D. Yu. Ilyevsky
L. V. Ivanova
E. Yu. Akulinushkina
P. A. Shesternya
O. V. Matveychuk
Yu. Yu. Grabovetskaya
A. A. Barakat
M. A. Korolev
E. V. Zonova
O. A. Georginova
I. V. Kolotilina
I. M. Marusenko
I. B. Vinogradova
O. B. Nesmeyanova
N. E. Grigoriadi
A. V. Petrov
D. G. Krechikova
T. V. Kropotina
S. P. Yakupova
V. I. Mazurov
Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)
Современная ревматология
axial psoriatic arthritis
non-interventional study
diagnostics
treatment tactics
title Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)
title_full Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)
title_fullStr Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)
title_full_unstemmed Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)
title_short Results of a non-interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real-life clinical practice (NiSaXPA)
title_sort results of a non interventional observational multicenter study of the management of patients with axial psoriatic arthritis in real life clinical practice nisaxpa
topic axial psoriatic arthritis
non-interventional study
diagnostics
treatment tactics
url https://mrj.ima-press.net/mrj/article/view/1498
work_keys_str_mv AT tvkorotaeva resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT eegubar resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT eyuloginova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT ylkorsakova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT eavasilenko resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT idyuilyevsky resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT lvivanova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT eyuakulinushkina resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT pashesternya resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT ovmatveychuk resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT yuyugrabovetskaya resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT aabarakat resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT makorolev resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT evzonova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT oageorginova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT ivkolotilina resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT immarusenko resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT ibvinogradova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT obnesmeyanova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT negrigoriadi resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT avpetrov resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT dgkrechikova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT tvkropotina resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT spyakupova resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa
AT vimazurov resultsofanoninterventionalobservationalmulticenterstudyofthemanagementofpatientswithaxialpsoriaticarthritisinreallifeclinicalpracticenisaxpa